Sino-Argi Leading Biosciences

Sino-Agri Leading Biosciences released its 2026 interim report. Total operating revenue was 6.823 billion yuan, up 1.15% year-on-year. Net profit attributable to the parent company was 124 million yuan, down 12.70% year-on-year. Net cash inflow from operating activities was 187 million yuan, an increase of 1.361 billion yuan year-on-year. The asset-liability ratio was 73.06%, gross margin was 5.74%, return on equity was 7.76%, and diluted earnings per share was 0.46 yuan. Total asset turnover was 1.19 times, and inventory turnover was 3.93 times. The number of shareholders was 12,000, and the top ten shareholders held 65.49% of total share capital.